Menssana Research

Executive Summary

Menssana Research is a pioneering diagnostics company based in Newark, New Jersey, that has been developing non-invasive breath tests for over three decades. Founded in 1988, the company specializes in analyzing volatile organic compounds (VOCs) in human breath to identify biomarkers for serious diseases such as lung cancer, breast cancer, and tuberculosis. Its technology offers a painless, radiation-free alternative to traditional diagnostic methods, potentially enabling earlier detection and improved patient outcomes. By leveraging breath analysis, Menssana aims to reduce healthcare costs and increase screening accessibility, particularly in underserved populations. Despite its long history, the company remains privately held and has not yet achieved widespread commercial deployment, suggesting it may be nearing a pivotal inflection point.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation or Approval for Lung Cancer Breath Test60% success
• Q4 2026Publication of Pivotal Clinical Trial Results for Breast Cancer Detection70% success
• Q2 2026Strategic Partnership or Licensing Agreement with Major Diagnostics Firm50% success